Table 2.
Associations of galectin-3 and fibulin-1 levels with clinical and glucometabolic parameters
| Galectin-3 | Fibulin-1 | |||
|---|---|---|---|---|
| Parameter | β (SE) | P-Value | β (SE) | P-Value |
| Age, per year | 0.16 (0.23) | 0.05 | 0.36 (0.12) | <0.001 |
| Sex | 0.04 (0.07) | 0.59 | −0.09 (2.75) | 0.29 |
| Ischemic heart disease | −0.01 (0.07) | 0.90 | −0.009 (2.71) | 0.92 |
| NYHA I + II vs. III + IV | 0.16 (0.09) | 0.06 | 0.08 (3.37) | 0.34 |
| Atrial fibrillation | 0.17 (0.07) | 0.03 | 0.17 (2.83) | 0.03 |
| Diabetes mellitus | 0.27 (0.07) | 0.001 | 0.16 (2.62) | 0.05 |
| eGFR, per ml/min/1.73 m2 | −0.49 (0.10) | <0.001 | −0.33 (0.06) | <0.001 |
| Metabolism | ||||
| BMI, per kg/m2 | −0.04 (0.006) | 0.63 | −0.12 (0.25) | 0.14 |
| FPG, per mmol/L | 0.19 (0.02) | 0.02 | −0.07 (1.37) | 0.44 |
| 2hPG, per mmol/L | 0.15 (0.01) | 0.09 | 0.26 (0.42) | 0.004 |
| HbA1C, per mmol/mol | 0.25 (0.16) | 0.02 | 0.21 (0.14) | 0.009 |
| HOMA-IR, per unit | 0.17 (0.01) | 0.06 | −0.08 (0.52) | 0.36 |
| Biomarkers | ||||
| NT-proBNP per pg/mL | 0.30 (0.12) | <0.001 | 0.38 (2.24) | <0.001 |
Univariable regression models
2hPG 2 h plasma glucose, BMI Body mass index, FPG Fasting plasma glucose, GFR Glomerular filtration rate, HOMA-IR Homeostatic model assessment of insulin resistance, NT-proBNP N-terminal pro B-natriuretic peptide, NYHA NYHA functional class